Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
dc.contributor.author | Parisinos, CA | |
dc.contributor.author | Wilman, HR | |
dc.contributor.author | Thomas, EL | |
dc.contributor.author | Kelly, M | |
dc.contributor.author | Nicholls, RC | |
dc.contributor.author | McGonigle, J | |
dc.contributor.author | Neubauer, S | |
dc.contributor.author | Hingorani, AD | |
dc.contributor.author | Patel, RS | |
dc.contributor.author | Hemingway, H | |
dc.contributor.author | Bell, JD | |
dc.contributor.author | Banerjee, R | |
dc.contributor.author | Yaghootkar, H | |
dc.date.accessioned | 2020-05-26T07:42:05Z | |
dc.date.issued | 2020-04-02 | |
dc.description.abstract | BACKGROUND: A non-invasive method to grade the severity of steatohepatitis and liver fibrosis is magnetic resonance imaging (MRI) based corrected T1 (cT1). We aimed to identify genetic variants influencing liver cT1 and use genetics to understand mechanisms underlying liver fibroinflammatory disease and its link with other metabolic traits and diseases. METHODS: First, we performed a genome-wide association study (GWAS) in 14,440 Europeans in UK Biobank with liver cT1 measures. Second, we explored the effects of the cT1 variants on liver blood tests, and a range of metabolic traits and diseases. Third, we used Mendelian randomisation to test the causal effects of 24 predominantly metabolic traits on liver cT1 measures. RESULTS: We identified six independent genetic variants associated with liver cT1 that reached GWAS significance threshold (p<5x10-8). Four of the variants (rs75935921 in SLC30A10, rs13107325 in SLC39A8, rs58542926 in TM6SF2, rs738409 in PNPLA3) were also associated with elevated transaminases and had variable effects on liver fat and other metabolic traits. Insulin resistance, type 2 diabetes, non-alcoholic fatty liver and BMI were causally associated with elevated cT1 whilst favourable adiposity (instrumented by variants associated with higher adiposity but lower risk of cardiometabolic disease and lower liver fat) was found to be protective. CONCLUSION: The association between two metal ion transporters and cT1 indicates an important new mechanism in steatohepatitis. Future studies are needed to determine whether interventions targeting the identified transporters might prevent liver disease in at risk individuals. | en_GB |
dc.description.sponsorship | Diabetes UK | en_GB |
dc.description.sponsorship | Wellcome Trust | en_GB |
dc.description.sponsorship | Innovate UK Knowledge Transfer Partnership | en_GB |
dc.identifier.citation | Published online 2 April 2020 | en_GB |
dc.identifier.doi | 10.1016/j.jhep.2020.03.032 | |
dc.identifier.grantnumber | 17/0005594 | en_GB |
dc.identifier.grantnumber | 206274/Z/17/Z | en_GB |
dc.identifier.grantnumber | KTP10271 | en_GB |
dc.identifier.other | S0168-8278(20)30194-X | |
dc.identifier.uri | http://hdl.handle.net/10871/121149 | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/32247823 | en_GB |
dc.rights | © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). | en_GB |
dc.subject | Magnetic resonance imaging | en_GB |
dc.subject | cT1 | en_GB |
dc.subject | fibrosis | en_GB |
dc.subject | genome-wide association study | en_GB |
dc.subject | metabolic syndrome | en_GB |
dc.subject | steatohepatitis | en_GB |
dc.title | Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-05-26T07:42:05Z | |
exeter.place-of-publication | Netherlands | en_GB |
dc.description | This is the final version. Available from Elsevier via the DOI in this record. | en_GB |
dc.description | Full data including individual cT1 and PDFF measures will be returned to UK Biobank and made publicly available via application (amsportal.ukbiobank.ac.uk). | en_GB |
dc.identifier.journal | Journal of Hepatology | en_GB |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2020-03-19 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2020-04-02 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-05-26T07:38:03Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2020-05-26T07:42:08Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).